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Introduction: The TH17 immune response plays a central role in the
pathogenesis of autoimmune diseases, implicating the TH17 “master
cytokine” IL-17A as the critical mediator of diseases such as human
and experimental crescentic glomerulonephritis (GN). However, the
relative importance of additional TH17 effector cytokines,
including IL-17F, in immune-mediated tissue injury remains to be
fully elucidated.
Methods: Here, we used a mouse model of acute crescentic GN
(nephrotoxic Nephritis) including interventional studies using IL-
17F-gene-deﬁcient mice, IL-17F-neutralizing antibodies, as well as
adoptive cell transfer experiments into Rag1-/- mice. Moreover, also
in the chronic model of pristane induced systemic lupus, IL-17F-
deﬁcient mice were analyzed.
Results: In a mouse model of acute crescentic GN, we identiﬁed
CD4+ T cells and T cells as the major cellular source of IL-17F in the
inﬂamed kidney. In our studies using IL-17F-gene-deﬁcient mice as
well as IL-17F-neutralizing antibodies, and adoptive cell transfer
experiments into Rag1-/- mice we demonstrated that CD4+ T cell-
derived IL-17F drives renal tissue injury in acute crescentic GN.
Moreover, also in the chronic model of pristane induced systemic
lupus, IL-17F-deﬁcient mice developed less severe disease with
respect to survival and renal injury. Finally, we show that IL-17F
induced expression of the chemokines CXCL1 and CXCL5 in kidney
cells, which recruited destructive neutrophils.
Conclusions: In conclusion, using gene-deﬁcient mice, neutralizing
antibodies and adoptive cell transfer experiments, we demonstrate
for the ﬁrst time that IL-17F promotes kidney injury in acute and
chronic experimental glomerulonephritis. Our data, which chal-
lenge the paradigm of IL-17A as being the unique TH17 master
cytokine, might be of direct importance for future anti- TH17/IL-17
treatment strategies in human autoimmune diseases.
P41
IL-33-MEDIATED EXPANSION OF TYPE
2 INNATE LYMPHOID CELLS
AMELIORATES PROGRESSIVE
GLOMERULOSCLEROSIS
Becker, M1, Riedel, JH1, Kopp, K1, Kaffke, A1, Düster, M1,
Brix, S1, Stahl, RAK1, Stockinger, B2, Panzer, U1,
Turner, JE1
1Universitätsklinikum Hamburg-Eppendorf, III. Medizinische Klinik,
Hamburg, Germany; 2The Francis Crick Institute, Mill Hill Laboratory, Lon-
don, United Kingdom
Introduction: Chronic kidney disease (CKD) affects around 10% of
the western population and is a major risk factor for cardiovascular
mortality. Regardless of the type of primary injury, glomerular
damage regularly results in progressive glomerulosclerosis with
proteinuria and deteriorating kidney function. Over the last years,
innate lymphoid cells (ILC) have been shown to play an important
role in the immune system’s response to different forms ofKidney International Reports (2016) 1, S1–S22infectious and non-infectious pathologies. Especially, IL-5- and IL-
13-producing type 2 ILC (ILC2) have been implicated in repair
mechanisms with the aim of restoring tissue integrity after injury.
Methods: ILC populations in the human and murine kidney were
analysed by ﬂow cytometry. ILC2 were expanded in mice by
treatment with IL-33. The effect of IL-33-mediated ILC2 expansion
was tested in a mouse model of progressive glomerulosclerosis that
is induced in BALB/c mice by injection of adriamycin.
Results: In the present study, we show that ILC populations are
present in the chronically inﬂamed human kidney. A detailed
characterization of kidney-residing ILC populations in mice
revealed that ILC2 are the most abundant ILC subtype in the mouse
kidney. Short-term IL-33 treatment lead to a sustained expansion of
IL-33R+ kidney ILC2 and ameliorated progressive glomerulo-
sclerosis and attenduated the loss of kidney function induced by
Adriamycin-injection in BALB/c mice. The IL-33 effect was inde-
pendent of T and B cells and depletion of ILC in IL-33 treated mice
abrogated the IL-33-mediated protection from progressive CKD.
The tissue-protective mechanisms employed by IL-5- and IL-13-
producing ILC2 included enhanced activation of alternatively
activated macrophages, recruitment of eosinophils and limitation of
neutrophil inﬂux by downregulation of neutrophil-attracting
chemokines.
Conclusions: In summary, we show that kidney-residing ILC2 can
be effectively expanded by IL-33 in the mouse kidney and are
central regulators of renal repair mechanisms. The presence of ILC
in the human kidney tissue identiﬁes ILC as attractive therapeutic
targets for chronic kidney disease in humans.
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Introduction: Acute kidney injury (AKI) is among the most
frequent causes for renal damage and associated with signiﬁcant
increase of morbidity and mortality. In rodent models for AKI it
was demonstrated that immune cells time dependently contribute
to tissue damage and repair, however there is a lack of data for
human AKI.
Methods: Urine of patients with AKI was processed and prepared
for ﬂow cytometry within 6 hours after acquisition. Cell counts of
immune and renoparenchymal cells were measured using ﬂow
cytometry. Kinetics of diverse cell subsets were investigated over
two weeks past renal failure.
Results: Renal epithelial cell numbers are increased shortly after
renal insult and decrease with recovery of the patients. They
correlate with creatinine and AKI stadium. Neutrophils (CD66b+),
Macrophages (CD36+, CD14+) and T cells (CD3+CD4+ and
CD3+CD8+) were detected in the urine of patients with AKI. While
urinary numbers of renal epithelial cells and neutrophils decreasedS19
